Respira Therapeutics, Inc. yakazivisa nhasi kuti murwere wekutanga muUnited States akaiswa muyedzo yakawanda yemutungamiri wayo wechigadzirwa, RT234-PAH (vardenafil inobatwa sehupfu hwakaoma inhaled treatment). Iyo VIPAH-PRN 2b yekuedza (Vardenafil Inhaled yePulmonary Arterial Hypertension - PRN) ichave nemapoka maviri akatevedzana anogamuchira RT234 seyero imwe chete inotungamirirwa neAxial Oscillating Sphere yakaoma poda inhaler. Chidzidzo ichi chakagadzirirwa kuongorora kuchengetedzeka uye kushanda kwekutanga kweRT234 kunyatsonatsiridza episodic zviratidzo uye kurovedza muviri muvanhu vari kurapwa pulmonary arterial hypertension (PAH) neNew York Heart Association (NYHA) Functional Kirasi II-III zviratidzo.
"Kutangwa kwekuedza kwekiriniki uku kunomiririra chiitiko chakakosha chekufema uye idanho rinotevera rinokosha mukukwanisa kupa varwere vePAH kurapwa kwakanyanya kuti vakwanise kutadza kufema, izvo zvinovatadzisa kuita mabasa emazuva ese," akadaro Carol Satler, PhD. , MD, Mutungamiri uye Chief Medical Officer weRespira. “Vanhu vanorwara nechirwere ichi chiri kupera simba avo vari kurapwa nemishonga inochengetedza vanhu vachiri kusangana nezvikamu zvekutadza kufema zvakanaka, kuneta nekutadza kuita maekisesaizi, uye pari zvino hakuna mishonga yekukurumidza kutanga yave kushandiswa ‘sezvinodiwa’ kuderedza zvirwere izvi. ”
"Kuita kuti varwere vePAH vawedzere kushanda ndicho chinhu chinokosha kuhutano hwavo hwepanyama uye hwepfungwa," akadaro Raymond L. Benza, MD, Mutungamiriri weChikamu cheCardiovascular Medicine paThe Ohio State University Wexner Medical Center. “Iye zvino neongororo yeRT234, tiri kuongorora kugona kwedu kusimudzira kurovedza muviri kana murwere achida. Rinogona kunge riri danho rakakura kumberi muhondo yedu nechirwere ichi. "
Iyo VIPAH-PRN 2b muedzo (RT234-PAH-CL202) idosi-yekukwira kudzidza kuti iongorore zvakanyanya shanduko yezviratidzo post dosing yeRT234 muzvidzidzo zvine PAH. Zvinofungidzirwa kuti inhaled RT234 (vardenafil inhalation powder) inogona kupa rubatsiro rwekurapa kwekushandiswa kwakanyanya kune varwere vane World Health Organization (WHO) Boka 1 Pulmonary Hypertension (PH) (Pulmonary Arterial Hypertension [PAH]) kuvandudza simba rekudzidzira uye kushanda mu zviitiko zvehupenyu hwezuva nezuva, pamwe nekudzikisa zviratidzo zvekuedza (semuenzaniso, dyspnea) uye zvinokanganisa zvinokanganisa hupenyu hwehupenyu.
ZVOKUBVA MUNYAYA INO:
- It is hypothesized that inhaled RT234 (vardenafil inhalation powder) may provide a therapeutic benefit for acute use in patients with World Health Organization (WHO) Group 1 Pulmonary Hypertension (PH) (Pulmonary Arterial Hypertension [PAH]) to improve exercise capacity and performance in activities of daily living, as well as reduce exertional symptoms (e.
- “The initiation of this clinical trial represents an important milestone for Respira and is a critical next step in potentially offering patients with PAH an acute treatment to manage their shortness of breath, which prevents them from performing normal daily duties,”.
- The study is designed to evaluate the safety and preliminary efficacy of RT234 to acutely improve episodic symptoms and exercise capacity in people being treated for pulmonary arterial hypertension (PAH) with New York Heart Association (NYHA) Functional Class II-III symptoms.
